BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2955245)

  • 1. D-1 dopamine receptor stimulation potentiates neurophysiological effects of bromocriptine in rats with lesions of the nigrostriatal dopamine pathway.
    Weick BG; Walters JR
    Neuropharmacology; 1987 Jun; 26(6):641-4. PubMed ID: 2955245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated stimulation of D-1 dopamine receptors increases the circling response to bromocriptine in rats with a 6-OHDA lesion.
    Rouillard C; Bédard P; Falardeau P; Di Paolo T
    Eur J Pharmacol; 1988 Nov; 157(2-3):125-33. PubMed ID: 2975996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
    Huang KX; Bergstrom DA; Ruskin DN; Walters JR
    Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus.
    Carlson JH; Bergstrom DA; Demo SD; Walters JR
    Synapse; 1990; 5(2):83-93. PubMed ID: 2309160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats.
    Robertson GS; Robertson HA
    Brain Res; 1986 Oct; 384(2):387-90. PubMed ID: 2946360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurophysiological investigation of effects of the D-1 agonist SKF 38393 on tonic activity of substantia nigra dopamine neurons.
    Carlson JH; Bergstrom DA; Weick BG; Walters JR
    Synapse; 1987; 1(5):411-6. PubMed ID: 2975067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D1- and D2-receptor interaction in turning behaviour induced by dopamine agonists in 6-hydroxydopamine-lesioned rats.
    Karlsson G; Jaton AL; Vigouret JM
    Neurosci Lett; 1988 May; 88(1):69-74. PubMed ID: 2969468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos.
    Robertson GS; Vincent SR; Fibiger HC
    Brain Res; 1990 Jul; 523(2):288-90. PubMed ID: 2144781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D1 receptor activation enhances sciatic nerve stimulation-induced inhibition of nigrostriatal dopamine neurons.
    Kelland MD; Freeman AS; Chiodo LA
    Synapse; 1989; 3(4):339-45. PubMed ID: 2525823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of dopamine D-1 and D-2 receptor subtype agonists on nigrostriatal opioid dynorphin and enkephalin immunostaining in 6-hydroxydopamine lesioned rats.
    Jiang HK; Wang JY
    Chin J Physiol; 1991; 34(4):413-25. PubMed ID: 1687937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SKF 38393 alters the rate-dependent D2-mediated inhibition of nigrostriatal but not mesoaccumbens dopamine neurons.
    Kelland MD; Freeman AS; Chiodo LA
    Synapse; 1988; 2(4):416-23. PubMed ID: 2973142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposing roles of dopamine D1 and D2 receptors in nigral gamma-[3H]aminobutyric acid release?
    Starr M
    J Neurochem; 1987 Oct; 49(4):1042-9. PubMed ID: 2957468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic grafts in the striatum reduce D1 but not D2 receptor-mediated rotation in 6-OHDA-lesioned rats.
    Robertson GS; Fine A; Robertson HA
    Brain Res; 1991 Jan; 539(2):304-11. PubMed ID: 1675908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
    Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
    Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioural evidence for the functionality of D-2 but not D-1 dopamine receptors at multiple brain sites in the 6-hydroxydopamine-lesioned rat.
    Fletcher GH; Starr MS
    Eur J Pharmacol; 1987 Jun; 138(3):407-11. PubMed ID: 2957221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.